Alnylam Pharmaceuticals, Inc.
$38.07B- Market cap
- $35.61B
- Debt
- +$4.12B
- Cash
- −$1.66B
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ALNY stock price vs CZR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CZR's multiple
Needs CZR P/E.
Implied fair value · at ALNY's multiple
Needs EPS (TTM) is negative, ALNY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALNY FY 2025 (ended Dec 31, 2025) · CZR FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
Capital structure 33% equity / 67% debt · EV / Revenue 1.50x · EV / EBITDA 4.22x
ALNY carries the larger enterprise value at $38.07B against $17.18B; CZR trades on the lower EV / Revenue multiple (1.50x vs 10.25x); CZR on the lower EV / EBITDA (4.22x vs 63.81x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Caesars Entertainment, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
5.22x
3.43x
Net debt / EBITDA
Leverage against operating earnings
4.13x
2.73x
Cash and equivalents
Liquid reserves on the balance sheet
$1.66B
$889.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ALNY vs MRNA
Sarepta Therapeutics, Inc.
ALNY vs SRPT
VERTEX PHARMACEUTICALS INC / MA
ALNY vs VRTX
BioNTech SE
ALNY vs BNTX
ACADIA PHARMACEUTICALS INC
ALNY vs ACAD
WYNN RESORTS LTD
ALNY vs WYNN
PENN Entertainment, Inc.
ALNY vs PENN
BOYD GAMING CORP
ALNY vs BYD
MGM Resorts International
ALNY vs MGM
LAS VEGAS SANDS CORP
ALNY vs LVS
$4.12B
$12.02B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.